All Stories

  1. Substituting a randomised placebo control group with a historical placebo control in an endometriosis pain trial: a case study re-evaluating trial data using historical control data from another trial

    Article • BMJ Open, July 2023, BMJ

    Dr Christian Seitz

  2. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)

    Article • Menopause, January 2023, Wolters Kluwer Health

    Dr Christian Seitz

  3. Endometrial hyperplasia in pre-menopausal women: A systematic review of incidence, prevalence, and risk factors

    Article • European Journal of Obstetrics & Gynecology and Reproductive Biology, April 2022, Elsevier

    Dr Christian Seitz

  4. Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure–response modelling and simulation

    Article • British Journal of Clinical Pharmacology, August 2021, Wiley

    Dr Christian Seitz

  5. Patients’ and clinicians’ perspectives on item importance, scoring, and clinically meaningful differences for the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS)

    Article • Health and Quality of Life Outcomes, January 2021, Springer Science + Business Media

    Dr Christian Seitz

  6. Validation of a menstrual pictogram and a daily bleeding diary for assessment of uterine fibroid treatment efficacy in clinical studies

    Article • Journal of Patient-Reported Outcomes, November 2020, Springer Science + Business Media

    Dr Christian Seitz

  7. Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2

    Article • European Journal of Obstetrics & Gynecology and Reproductive Biology, September 2020, Elsevier

    Dr Christian Seitz

  8. Development and content validation of two new patient-reported outcome measures for endometriosis: the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS)

    Article • Journal of Patient-Reported Outcomes, February 2020, Springer Science + Business Media

    Dr Christian Seitz

  9. Pictorial methods to assess heavy menstrual bleeding in research and clinical practice: a systematic literature review

    Article • BMC Women s Health, February 2020, Springer Science + Business Media

    Dr Christian Seitz

  10. Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study

    Article • Fertility and Sterility, February 2019, Elsevier

    Dr Christian Seitz

  11. Efficacy and safety of the selective progesterone receptor modulator (PRM) vilaprisan: a sub-analysis of the asteroid 1 trial by ethnicity

    Article • Fertility and Sterility, September 2018, Elsevier

    Dr Christian Seitz

  12. A systematic review of methods to measure menstrual blood loss

    Article • BMC Women s Health, August 2018, Springer Science + Business Media

    Dr Christian Seitz

  13. Patterns of missing data in the use of the endometriosis symptom diary

    Article • BMC Women s Health, June 2018, Springer Science + Business Media

    Dr Christian Seitz

  14. Letter to the editor in response to “Minimal clinically important difference for pain on the VAS scale and the relation to quality of life in women with endometriosis” by Wickström and Edelstam

    Article • Sexual & Reproductive Healthcare, March 2018, Elsevier

    Dr Christian Seitz

  15. Dienogest 2 mg Daily in the Treatment of Adolescents with Clinically Suspected Endometriosis: The VISanne Study to Assess Safety in ADOlescents

    Article • Journal of Pediatric and Adolescent Gynecology, October 2017, Elsevier

    Dr Christian Seitz

  16. Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids

    Article • Contemporary Clinical Trials, April 2017, Elsevier

    Dr Christian Seitz

  17. Results of the asteroid (assess safety and efficacy of vilaprisan in patients with uterine fibroids) 1 study: a phase 2, placebo-controlled dose finding study

    Article • Fertility and Sterility, September 2016, Elsevier

    Dr Christian Seitz

  18. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women

    Article • Human Reproduction, June 2016, Oxford University Press (OUP)

    Dr Christian Seitz

  19. Measuring The Symptoms And Impacts Of Endometriosis: Psychometric Validation Of The Endometriosis Symptom Diary And Endometriosis Impact Scale

    Article • Value in Health, May 2015, Elsevier

    Dr Christian Seitz

  20. Safety and tolerability of dienogest in endometriosis: pooled analysis from the European clinical study program

    Article • International Journal of Women s Health, April 2015, Taylor & Francis

    Dr Christian Seitz

  21. Assessing the content validity of the endometriosis symptom diary and endometriosis impact scale

    Article • Value in Health, May 2014, Elsevier

    Dr Christian Seitz

  22. Validation of a new menstrual pictogram (superabsorbent polymer-c version) for use with ultraslim towels that contain superabsorbent polymers

    Article • Fertility and Sterility, February 2014, Elsevier

    Dr Christian Seitz

  23. A new menstrual pictogram for use with feminine products that contain superabsorbent polymers

    Article • Fertility and Sterility, December 2013, Elsevier

    Dr Christian Seitz

  24. Validation of the SF-36 in patients with endometriosis

    Article • Quality of Life Research, July 2013, Springer Science + Business Media

    Ms Mireia Raluy Callado, Dr Christian Seitz

  25. Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis

    Article • International Journal of Gynecology & Obstetrics, March 2012, Wiley

    Dr Christian Seitz

  26. How can we measure endometriosis-associated pelvic pain?

    Article • Journal of Endometriosis, January 2012, Wichtig

    Dr Christian Seitz

  27. Treatment of endometriosis in different ethnic populations: a meta-analysis of two clinical trials

    Article • BMC Women s Health, January 2012, Springer Science + Business Media

    Dr Christian Seitz

  28. Verträglichkeit von Dienogest in der Endometriosetherapie: Analyse gepoolter Daten aus dem klinischen Entwicklungsprogramm

    Article • Geburtshilfe und Frauenheilkunde, October 2011, Thieme Publishing Group

    Dr Christian Seitz

  29. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment

    Article • Archives of Gynecology and Obstetrics, June 2011, Springer Science + Business Media

    Dr Christian Seitz

  30. Corrigendum to “A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis” [International Journal of Gynecology and Obstetrics 108 (2010) 21-25]

    Article • International Journal of Gynecology & Obstetrics, January 2011, Wiley

    Dr Christian Seitz

  31. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study

    Article • European Journal of Obstetrics & Gynecology and Reproductive Biology, August 2010, Elsevier

    Dr Christian Seitz

  32. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial

    Article • Human Reproduction, January 2010, Oxford University Press (OUP)

    Dr Christian Seitz

  33. Defining a minimal clinically important difference for endometriosis-associated pelvic pain measured on a visual analog scale: analyses of two placebo-controlled, randomized trials

    Article • Health and Quality of Life Outcomes, January 2010, Springer Science + Business Media

    Dr Christian Seitz

  34. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis

    Article • International Journal of Gynecology & Obstetrics, October 2009, Wiley

    Dr Christian Seitz

  35. O301 Safety of dienogest for the treatment of endometriosis: A 24-week, randomised, open-label trial versus leuprolide acetate

    Article • International Journal of Gynecology & Obstetrics, October 2009, Wiley

    Dr Christian Seitz

  36. O835 Long-term experience with dienogest for the treatment of endometriosis: a one-year, open-label, follow-up study

    Article • International Journal of Gynecology & Obstetrics, October 2009, Wiley

    Dr Christian Seitz

  37. PIH28 VALIDATION OF THE SF—36 IN PATIENTS WITH ENDOMETRIOSIS

    Article • Value in Health, October 2009, Elsevier

    Dr Christian Seitz

  38. O341 Minimally clinically important difference for endometriosis associated pelvic pain measured on a visual analogue scale

    Article • International Journal of Gynecology & Obstetrics, October 2009, Wiley

    Dr Christian Seitz

  39. Safety of dienogest in the long-term treatment of endometriosis: a one-year, open-label, follow-up study

    Article • Fertility and Sterility, September 2009, Elsevier

    Dr Christian Seitz

  40. A double-blind placebo-controlled trial investigating the efficacy of 12 weeks of dienogest 2 mg/day for the treatment of endometriosis-associated pain

    Article • Fertility and Sterility, September 2008, Elsevier

    Dr Christian Seitz

  41. Structurally diverse forms of HLA-B27 molecules are displayed in vivo in a cell type-dependent manner

    Article • Human Immunology, April 2000, Elsevier

    Dr Christian Seitz

  42. The monoclonal antibody HCA2 recognises a broadly shared epitope on selected classical as well as several non-classical hla class i molecules

    Article • Molecular Immunology, September 1998, Elsevier

    Dr Christian Seitz